1998
Prognostic indicators of survival in ALS
Stambler N, Charatan M, Cedarbaum J. Prognostic indicators of survival in ALS. Neurology 1998, 50: 66-72. PMID: 9443459, DOI: 10.1212/wnl.50.1.66.Peer-Reviewed Original ResearchConceptsStudy entrySerum chlorideMuscle strength lossBaseline demographic characteristicsLength of survivalRisk of mortalityClinical laboratory testsGreater weight lossCiliary neurotrophic factorRecombinant human ciliary neurotrophic factorHuman ciliary neurotrophic factorPlacebo groupPulmonary functionSymptom onsetPrognostic factorsMulticenter studyShorter survivalVital capacityNeurotrophic factorPrognostic indicatorRespiratory acidosisSurvival timeProbability of survivalDisease severityWeight loss
1990
Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR)
Cedarbaum JM, Silvestri M, Clark M, Toy L, Harts A, Green-Parsons A, McDowell FH. Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR). Journal Of Neural Transmission: Parkinson's Disease A And Dementia Section 1990, 2: 205-213. PMID: 2257060, DOI: 10.1007/bf02257651.Peer-Reviewed Original ResearchConceptsStandard SinemetMotor response fluctuationsResponse fluctuationsSinemet CRDisease patientsControlled-release levodopa/carbidopaLevodopa/carbidopaLong-term treatmentParkinson's disease patientsLong-term managementAntiparkinson effectEligible patientsMost patientsMedication dosesInterdose intervalClinical trialsParkinson's diseaseUseful adjunctPatientsSinemetDiseaseYearsCarbidopaAdjunctDose